Drug intelligence / Profile preview

Cyclosporine + Prednisone

Development stage
Unknown
Lead developer
Sandoz
Administration
Intravenous, Oral
01

Overview

Cyclosporine + prednisone is a combination therapy used primarily for immunosuppression in various conditions. This combination leverages the complementary mechanisms of both drugs to achieve enhanced therapeutic effects while potentially allowing for lower doses of each individual medication. ## Therapeutic Uses The combination of cyclosporine and prednisone has been studied and used in several medical conditions: 1. **Pemphigus Vulgaris**: Clinical studies have shown that combined therapy with cyclosporine and prednisone is more effective than prednisone alone in treating pemphigus vulgaris. Patients receiving the combination therapy achieved clinical remission more quickly, with new blister formation ceasing after approximately 11 days compared to 20.5 days with prednisone alone[1][4]. Hospital stays were also significantly shorter for patients on the combination therapy (32.6 days versus 50.7 days)[1]. 2. **Refractory Celiac Disease**: The combined administration of prednisone and cyclosporine has proven to be a clinically effective treatment option for patients with refractory celiac disease who don't respond to steroids alone or cannot tolerate other immunosuppressants like azathioprine[2]. 3. **Minimal Change Nephrotic Syndrome (MCNS)**: Studies indicate that combined cyclosporine and prednisolone therapy in adult patients with MCNS allows for earlier remission and reduced prednisolone dosage[3]. 4. **Organ Transplantation**: Cyclosporine is commonly used in combination with prednisone and other immunosuppressants to prevent organ rejection in kidney, liver, and heart transplants[5][6]. ## Mechanism of Action The effectiveness of this combination stems from the complementary mechanisms of both drugs: - **Cyclosporine**: Acts as a calcineurin inhibitor that specifically targets T-cell activation. It binds to cyclophilin-1 inside cells, forming a complex that inhibits calcineurin. This prevents the dephosphorylation and activation of nuclear factor of activated T cells (NF-AT), which normally triggers inflammatory reactions. By inhibiting IL-2 production and other cytokines, cyclosporine effectively suppresses T-cell proliferation and immune response[5]. - **Prednisone**: As a corticosteroid, prednisone has broad anti-inflammatory and immunosuppressive effects, acting on multiple components of the immune system. The combination allows for potentially lower doses of each medication while maintaining or enhancing therapeutic efficacy, which may reduce side effects associated with higher doses of either drug alone. ## Administration and Dosing Dosing regimens vary by condition, but examples from studies include: - For pemphigus vulgaris: Cyclosporine at 5 mg/kg/day with prednisone at 60-80 mg/day initially, with cyclosporine doses adjusted to maintain plasma levels of 100-150 ng/L[1]. - For refractory celiac disease: Initial treatment with cyclosporine (5 mg/kg IV daily) combined with prednisone (60 mg IV daily), later transitioning to oral administration with cyclosporine plasma levels maintained between 65-96 ng/ml[2]. ## Side Effects and Monitoring Patients on this combination therapy require careful monitoring for: - Renal function, as cyclosporine can cause nephrotoxicity - Blood pressure, as both medications can contribute to hypertension - Blood glucose levels, as prednisone can cause hyperglycemia - Electrolyte balance, particularly potassium levels - Liver function The combination therapy should be used with caution and requires regular medical supervision to adjust dosages and monitor for adverse effects.

Brand names
SandIMMUNENeoralGengraf
Other names
ciclosporin + prednisone
02

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)GR (Glucocorticoid receptor)CN (Calcineurin)

Beyond the preview

Go deeper on Cyclosporine + Prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclosporine + Prednisone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call